AI English summary of an SEC filing — figures as filed
Merck MRKThe company said worldwide sales were $16.7 billion in Q3 2024, up 4% from the same period a year earlier, or 7% excluding the unfavorable effect of foreign exchange. It cited higher oncology franchise sales, led by Keytruda and Welireg, as the main growth driver.
Key points
AI summaryThe company said worldwide sales were $16.7 billion in Q3 2024, up 4% from the same period a year earlier, or 7% excluding the unfavorable effect of foreign exchange. It cited higher oncology franchise sales, led by Keytruda and Welireg, as the main growth driver.
Worldwide Keytruda sales rose 17% in Q3 2024 and 18% on a year-to-date basis through January–September, the company said, or 21% and 22%, respectively, excluding the unfavorable effect of foreign exchange. The company attributed U.S. sales growth to increased uptake in earlier-stage indications and higher pricing.
Merck said it acquired EyeBio for $1.2 billion in July 2024 and incurred $207 million in transaction costs. It accounted for the deal as an asset acquisition and recognized $1.35 billion, or $0.52 per share, as Research and development expenses.
The company said operating cash flow for 2024 through January–September rose to $18.0 billion from $12.8 billion a year earlier, which it attributed to stronger operating performance. Milestone and option payments tied to collaborations, totaling $370 million, reduced operating cash flow.
Key figures
Quarter ended September 30, 2024
- Revenue
- $16.7B
- Net income
- $3.2B
- EPS
- $1.24
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Worldwide sales of $16.7 billion in Q3 2024
The company said worldwide sales were $16.7 billion in Q3 2024, up 4% from the same period a year earlier, or 7% excluding the unfavorable effect of foreign exchange. It cited higher oncology franchise sales, led by Keytruda and Welireg, as the main growth driver.
Source · Based on the MD&A text of the filing
Keytruda worldwide sales up 17% in Q3, 9 months 18%
Worldwide Keytruda sales rose 17% in Q3 2024 and 18% on a year-to-date basis through January–September, the company said, or 21% and 22%, respectively, excluding the unfavorable effect of foreign exchange. The company attributed U.S. sales growth to increased uptake in earlier-stage indications and higher pricing.
Source · Based on the MD&A text of the filing
EyeBio acquisition $1.2 billion, R&D expense $1.35 billion recognized
Merck said it acquired EyeBio for $1.2 billion in July 2024 and incurred $207 million in transaction costs. It accounted for the deal as an asset acquisition and recognized $1.35 billion, or $0.52 per share, as Research and development expenses.
Source · Based on the MD&A text of the filing
Operating cash flow $18.0 billion in 2024 January–September
The company said operating cash flow for 2024 through January–September rose to $18.0 billion from $12.8 billion a year earlier, which it attributed to stronger operating performance. Milestone and option payments tied to collaborations, totaling $370 million, reduced operating cash flow.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…